products
adjuvants
key ingredients to
effective vaccines
benefits of adjuvants
current vaccine challenges
our solutions
publications
key scientists
vaccines
tb vaccine
leishmaniasis vaccine
leprosy vaccine
diagnostics
tb diagnostics
leishmania diagnostics
leprosy diagnostics
chagas diagnostics
sales contact
therapeutics
tb drug discovery
| |
Tuberculosis Vaccine
The Challenge
Currently there is no universally effective TB vaccine. The vaccine used in many countries over the past 90 years, Bacillus Calmette-Guerin (BCG), is not ideal: BCG has low or no efficacy in many parts of the world against pulmonary TB; it induces granuloma, necrosis, and leaves a scar; requires cold chain for delivery; and only protects during childhood and early adolescence.
Our Solution
Our scientists are focused on a next-generation vaccine with the capability to prevent and possibly treat MDR-TB infection and disease progression. Following the selection of novel antigens, chosen based on rigorous selection criteria including antigenicity, immunogenicity, and protection, we generated new fusion proteins for evaluation in both pre- and post-challenge settings. Currently, we are optimizing our vaccine for clinical testing.
In collaboration with GlaxoSmithKline, we scanned the entire genome of M. tuberculosis for vaccine antigens. This resulted in the identification of the dominant proteins capable of stimulating protective immune responses. Most importantly, this collaboration resulted in the development of the world's first defined vaccine for tuberculosis. GSK is conducting Phase I testing of this novel vaccine candidate.
We are also participating in the development of effective, low-cost diagnostic tests for TB.
Publications
Bertholet S., Ireton G, Ordway D, Windish HP, Pine SO, Kahn M, Phan T, Orme I, Vedvick TS, Baldwin SL, Coler RN, Reed SG. 2010 A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobaterium tuberculosis. Science Translational Medicine 2:53 53ra74
Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, Reed SG. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol. 2008 Dec 1; 181(11):7948-57. PMID: 19017986
Steven G. Reed, Rhea N. Coler, Wilfried Dalemans, Esterlina V. Tan, Eduardo C. DeLa Cruz, Randall J. Basaraba, Ian M. Orme, Yasir A. W. Skeiky, Mark R. Alderson, Karen D. Cowgill, Jean-Paul Prieels, Rodolfo M. Abalos, Marie-Claude Dubois, Joe Cohen, Pascal Mettens, and Yves Lobet. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A. 2009 February 17; 106(7): 2301—2306. doi: 10.1073/pnas.0712077106.
Key Scientists
Rhea Coler
Susan Baldwin
Mark Orr
Lance Ching
Hillarie Windish
|
